Mimedx Group Inc

0.00 (0.00%)
Products, Regulatory

Mimedx Reports Top-Line Data From Two Late-Stage Musculoskeletal Trials With Proprietary Amniotic Tissue Technology

Published: 09/13/2021 11:55 GMT
Mimedx Group Inc (MDXG) - Mimedx Reports Top-line Data From Two Late-stage Musculoskeletal Trials With Proprietary Amniotic Tissue Technology.
Mimedx Group Inc - Phase 2b Knee Osteoarthritis (koa) Study Top-line Interim Results Demonstrate Varied Efficacy Signals Between Patient Cohorts.
Mimedx Group Inc - Company to Pursue Phase 3 Koa Confirmatory Studies.
Mimedx Group Inc - Initial Review of Phase 3 Plantar Fasciitis Trial Data Does Not Support a Biologics License Application (bla) Filing at This Time.
Mimedx Group - Top-line Results From an Interim Analysis of Six-month Efficacy Data for Phase 2b Clinical Trial for Koa Did Not Meet Primary Endpoints.
Mimedx Group Inc - Phase 3 Pf Study Did Not Meet Its Primary Endpoint, and Company Will Not Pursue a Bla for This Indication at This Time.
Mimedx Group Inc - Throughout Both Studies, Mdhacm Product Was Found Safe and Well-tolerated.
Mimedx - Plans to Meet With FDA to Review Findings and Determine Appropriate Path Forward Toward Initiation of Phase 3 Clinical Trials in Koa.